Thomas Hutson, DO, PharmD, PhD, FACP presents the latest findings from the CLEAR trial on lenvatinib + pembrolizumab vs sunitinib in patients with advanced renal cell carcinoma with or without bone metastases.
Thomas E. Hutson, DO, PharmD, PhD, FACP
Advertisement
Articles by Thomas E. Hutson, DO, PharmD, PhD, FACP
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts NDA for Zanzalintinib Plus Atezolizumab in Pretreated mCRC
2
HPV Vaccination and Evolving Screening Strategies Continue to Shape Cervical Cancer Prevention Efforts
3
Retrospective, Real-World Analysis Shows Improved OS With Apalutamide Over Darolutamide in mCSPC
4
Five Under 5: Top Oncology Videos for the Week of 1/25
5